PDF(Pubmed)
Abstract：
Ovarian cancer is an umbrella term covering a number of distinct subtypes. Endometrioid and clear-cell ovarian carcinoma are endometriosis-associated ovarian cancers (EAOCs) frequently arising from ectopic endometrium in the ovary. The mechanistic target of rapamycin (mTOR) is a crucial regulator of cellular homeostasis and is dysregulated in both endometriosis and endometriosis-associated ovarian cancer, potentially favouring carcinogenesis across a spectrum from benign disease with cancer-like characteristics, through an atypical phase, to frank malignancy. In this review, we focus on mTOR dysregulation in endometriosis and EAOCs, investigating cancer driver gene mutations and their potential interaction with the mTOR pathway. Additionally, we explore the complex pathogenesis of transformation, considering environmental, hormonal, and epigenetic factors. We then discuss postmenopausal endometriosis pathogenesis and propensity for malignant transformation. Finally, we summarize the current advancements in mTOR-targeted therapeutics for endometriosis and EAOCs.
摘要：
卵巢癌是涵盖许多不同亚型的总称。子宫内膜样和透明细胞卵巢癌是子宫内膜异位症相关的卵巢癌（EAOC），通常由卵巢中的异位子宫内膜引起。雷帕霉素的机制靶标（mTOR）是细胞内稳态的关键调节因子，在子宫内膜异位症和子宫内膜异位症相关卵巢癌中失调，从具有癌症样特征的良性疾病中，可能有利于癌症发生，通过一个非典型的阶段，弗兰克·恶性肿瘤。在这次审查中,我们关注子宫内膜异位症和EAOCs中的mTOR失调，研究癌症驱动基因突变及其与mTOR通路的潜在相互作用。此外,我们探索转化的复杂发病机理，考虑到环境，荷尔蒙，和表观遗传因素。然后我们讨论绝经后子宫内膜异位症的发病机制和恶变倾向。最后,我们总结了目前mTOR靶向治疗子宫内膜异位症和EAOCs的研究进展.
